In this study, we assessed the potential of targeting MCAK in cell-line models of triple-negative breast cancer (TNBC) because MCAK/Kif2C is highly expressed in breast cancer [48,49,50], and because anti-MT agents are often first-line therapies for TNBC, which frequently become resistant to these drugs [51]. Here, KIF2C is linked to triple-negative breast carcinoma.